Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07909031). This is a study registration, not published results. Lead sponsor: Crescent Biopharma, Inc.. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 219 participants (ESTIMATED). Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC), Esophageal Squamous Cell Carcinoma (ESCC), Ovarian Cancer, Endometrial Cancer, Cervical Cancer Metastatic, Non-small Cell Lung Cancer (NSCLC). Interventions: DRUG: CR-002. Primary outcome measures: Part 1: Dose Escalation - incidence and nature of dose-limiting toxicities , From the first dose of study drug up until approximately 1 month; Part 1: Dose Escalation - characterization of the maximum tolerated dose, if applicable , From the first dose of study drug up until approximately 1 month; All Parts - incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events , From the first dose of study drug until 90 days after the last dose of study drug; All Parts - incidence and severity of TEAEs leading to dose modifications , From the first dose of study drug until 90 days after the last dose of study drug; All Parts - incidence and severity of TEAEs leading to treatment discontinuation , From the first dose of study drug until 90 days after the last dose of study drug. Brief summary: The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.